reports
Imagin Medical Inc: 1 director
A director at Imagin Medical Inc bought 150,000 shares at 0.326USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Imagin Medical to Present at the First Annual BioTuesdays Pre-JPM Virt...
Imagin Medical to Present at the First Annual BioTuesdays Pre-JPM Virtual Conference VANCOUVER, British Columbia and BOSTON, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announced that management will present an update on the Company’s business at the first annual on Tuesday, December 10, 2019 at 12:00 p.m. Eastern Time. The presentation will be broadcast live and archived on the Company's website at under "Events & Presentations.” About Imagin Medical Imagin Medical is a surgical ima...
Imagin Medical Confirms Functional Units on Schedule for Product Desig...
Imagin Medical Confirms Functional Units on Schedule for Product Design Verification VANCOUVER, British Columbia and BOSTON, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported further progress toward verification of its i/Blue Imaging System functional product. The i/Blue System is currently in the design verification stage of the development process. Since Imagin’s last progress update on July 15, 2019, the Company has purchased and received components for the initial build of the f...
Imagin Medical Announces Social Media Campaign Launch
Imagin Medical Announces Social Media Campaign Launch VANCOUVER, British Columbia and BOSTON, Oct. 17, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) is pleased to announce the launch of new social media campaigns via Twitter, Facebook and LinkedIn. The primary goal of these new campaigns is to provide patients suffering from bladder cancer, their loved ones and the general public with an online resource to better understand the disease state as well as to provide access to up-to-date information on this ...
Imagin Medical Announces Meeting Regarding i/Blue’s Regulatory Pathw...
Imagin Medical Announces Meeting Regarding i/Blue’s Regulatory Pathway VANCOUVER, British Columbia and BOSTON, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announced it recently met with the U.S. Food and Drug Administration (“FDA” or the “Agency”) to discuss its premarket approval regulatory pathway for marketing authorization. Based on the Company’s continued collaborative discussions with the Agency, Imagin anticipates pursing approval for the i/BlueTM Imaging System through a regulat...
Imagin Medical Reports Fiscal 2019 Third Quarter Results
Imagin Medical Reports Fiscal 2019 Third Quarter Results VANCOUVER, British Columbia and BOSTON, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported financial results for the three months ended June 30, 2019. All amounts, unless otherwise specified, are expressed in Canadian dollars and are presented in accordance with International Financial Reporting Standards (IFRS). Recent Corporate Developments In April 2019, Imagin reached a major product development milestone with completion of...
Imagin Medical Reports Progress in i/Blueâ„¢ Imaging System Functional...
Imagin Medical Reports Progress in i/Blue™ Imaging System Functional Unit Development Phase VANCOUVER, British Columbia and BOSTON, July 15, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported continued progress toward verification of its i/Blue functional prototype product. At the recent American Urology Association Meeting, Imagin held private focus groups with leading urologists to demonstrate the first i/Blue functional prototype product. Input from these meetings, and the overwhelmingly pos...
Imagin Medical Announces Stock Option Grant
Imagin Medical Announces Stock Option Grant VANCOUVER, British Columbia and BOSTON, June 24, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (the “Company”) announced that, under its stock option plan, it has granted incentive stock options to a consultant of the Company to acquire an aggregate of 900,000 common shares at a price of $0.10 per share, for a period of five years from the date of grant. About Imagin MedicalImagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer du...
Imagin Medical Reports Fiscal 2019 Second Quarter Results
Imagin Medical Reports Fiscal 2019 Second Quarter Results VANCOUVER, British Columbia and BOSTON, June 11, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported financial results for the three months ended March 31, 2019. All amounts, unless otherwise specified, are expressed in Canadian dollars and are presented in accordance with International Financial Reporting Standards (IFRS). Recent Corporate Developments Imagin completed the Proof of Concept Phase of the redesigned i/Blue™ Imaging System...
Imagin Medical to Report Second Fiscal Quarter 2019 Financial Results ...
Imagin Medical to Report Second Fiscal Quarter 2019 Financial Results on June 11, 2019 – Conference Call to Follow VANCOUVER, British Columbia and BOSTON, June 03, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”), an emerging leader in the development and commercialization of advanced medical imaging technologies, announced today that its financial results for the second fiscal quarter ended March 31, 2019, will be released after market close on Tuesday, June 11, 2019. Imagin management will host a confere...
Imagin Medical Welcomes World-Renowned Bladder Cancer Expert Dr. Ashis...
Imagin Medical Welcomes World-Renowned Bladder Cancer Expert Dr. Ashish M. Kamat to Its Scientific Board of Advisors VANCOUVER, British Columbia and BOSTON, April 17, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announced that Dr. Ashish M. Kamat has joined its Scientific Advisory Board. Dr. Kamat has been named by Expertscape as the world’s top-rated expert in urinary bladder neoplasms. Dr. Kamat has extensive experience with cystoscopic procedures, has been a principal investigator for multiple ...
Imagin Medical Completes Assembly of i/Blueâ„¢ Imaging System Function...
Imagin Medical Completes Assembly of i/Blue™ Imaging System Functional Unit VANCOUVER, British Columbia and BOSTON, April 02, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announced that it reached the first step of a major product development milestone with completion of the i/Blue Imaging System’s Functional Unit, which has successfully met the Company’s pre-established performance expectations. Following the typical product development path for a new medical technology, the Company is working ...
Imagin Medical Reports Fiscal 2019 First Quarter Results
Imagin Medical Reports Fiscal 2019 First Quarter Results VANCOUVER, British Columbia and BOSTON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported financial results for the three months ended December 31, 2018. All amounts, unless otherwise specified, are expressed in Canadian dollars and are presented in accordance with International Financial Reporting Standards (IFRS). Recent Corporate Developments Completed, via Imagin’s opto-electronic design firm, Optel, Inc., the Proof of Con...
Imagin Medical to Report First Fiscal Quarter 2019 Financial Results o...
Imagin Medical to Report First Fiscal Quarter 2019 Financial Results on February 27, 2019 – Conference Call to Follow VANCOUVER, British Columbia and BOSTON, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”), an emerging leader in the development and commercialization of advanced medical imaging technologies, announced today that its financial results for the first fiscal quarter ended December 31, 2018, will be released after market close on Wednesday, February 27, 2019. Imagin management will host...
Imagin Medical to Present at Noble Capital Markets’ 15th Annual Inve...
Imagin Medical to Present at Noble Capital Markets’ 15th Annual Investor Conference VANCOUVER, British Columbia and BOSTON, Jan. 23, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”), an emerging leader in the development and commercialization of advanced medical imaging technologies, announced today management will present an update on the Company’s business at NobleConXV, Noble Capital Markets’ Fifteenth Annual Investor Conference, on Tuesday, January 29, 2019, at 12:00 p.m. Eastern Time at the W Hotel in F...
Imagin Medical Posts New Presentation on Its Website
Imagin Medical Posts New Presentation on Its Website VANCOUVER, British Columbia and BOSTON, Jan. 09, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today announced that, ahead of its planned meetings with members of the investment community over the coming weeks, it has made its updated corporate presentation available on the Company’s website. The presentation can be accessed by visiting the Investors section of . About Imagin Medical Imagin is developing powerful new imaging solutions for the detectio...
Imagin Medical Reports Fiscal Year End 2018 Results
Imagin Medical Reports Fiscal Year End 2018 Results VANCOUVER, British Columbia and BOSTON, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) today reported financial results for the year ended September 30, 2018. All amounts, unless otherwise specified, are expressed in Canadian dollars and are presented in accordance with International Financial Reporting Standards (IFRS). Select Corporate Developments Since Beginning of Fiscal 2018 Closed two non-brokered Private Placements for gross proceeds of...
Imagin Medical Announces Results Of Annual Meeting Of Shareholders
Imagin Medical Announces Results Of Annual Meeting Of Shareholders VANCOUVER, British Columbia and BOSTON, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) is pleased to announce the results of its Annual General Meeting of Shareholders (the “Meeting”) that was held yesterday. All of the matters put forward before the shareholders, as set out in the Company's management information circular dated November 15, 2018, were approved by the requisite majority of votes cast at the Meeting. Specifica...
Imagin Medical Comments on Recent Promotional Activity Pursuant to OTC...
Imagin Medical Comments on Recent Promotional Activity Pursuant to OTC Markets Request VANCOUVER, British Columbia and BOSTON, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) wishes to make the following statements regarding certain market activity surrounding its common shares (the "Common Shares"). On November 26, 2018, the Company was notified by the OTC Markets about certain promotional emails distributed in relation to its Common Shares from November 23 through November 26, 2018. Based ...
Imagin Medical Receives Approximately $1 Million From Exercise of Warr...
Imagin Medical Receives Approximately $1 Million From Exercise of Warrants VANCOUVER, British Columbia and BOSTON, Oct. 31, 2018 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”) announced today that it has received proceeds of CA$954,854 as a result of the exercise of 9,533,540 previously issued common share purchase warrants (the “Warrants”). The exercised Warrants were issued in connection with the Company’s public offering of units completed in two tranches in October 2017 and were set to expire on October ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.